Source - SMW
C4X Discovery Holdings presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11 Nov in Washington, DC.

C4XD's lead programme, Orexin-1, aims to treat addiction by targeting the 'craving' process itself and can be applied across a broad range of substance use disorders. 

Chief executive Clive Dix said: 'This set of studies strengthens C4XD's pre-clinical data package for our lead Orexin-1 antagonist programme. 

'We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control. 

'This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions.' 

At 9:54am: (LON:C4XD) C4x Discovery Holdings Plc share price was 0p at 79p